Journal of interventional cardiology最新文献

{"title":"Drug-Coated Balloons for Acute Myocardial Infarction: A Metaanalysis of Randomized Clinical Trials","authors":"Yuxuan Zhang,&nbsp;Delong Chen,&nbsp;Qichao Dong,&nbsp;Yi Xu,&nbsp;Jiacheng Fang,&nbsp;Huaqing Zhang,&nbsp;Jun Jiang","doi":"10.1155/2022/4018771","DOIUrl":"10.1155/2022/4018771","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. The role of a drug-coated balloon (DCB) in the treatment of acute myocardial infarction (AMI) is not well established. <i>Methods</i>. Five databases were searched for randomized controlled trials that compared DCB with stents in the treatment of AMI from their inception to 30 July 2021. The primary clinical endpoint was major adverse cardiac events (MACEs). Summary estimations were conducted using fixed-effects analysis complemented by several subgroups. The protocol was registered with PROSPERO (https://clinicaltrials.gov/ct2/show/CRD42021272886). <i>Results</i>. A total of 4 randomized controlled trials with 485 patients were included. On routine clinical follow-up, DCB was associated with no difference in the incidence of MACEs compared with control (risk ratio [RR] 0.59 [0.31 to 1.13]; <i>P</i> = 0.11). DCB was associated with similar MACEs compared with drug-eluting stent and lower MACEs compared with bare-metal stent. There was no difference between DCB and control in terms of all-cause mortality, cardiovascular mortality, stent thrombosis, target lesion revascularization, and minimal lumen diameter during follow-up. However, DCB was associated with a lower incidence of myocardial infarction (RR 0.16 [0.03 to 0.90]; <i>P</i> = 0.04) and lower late lumen loss (mean difference −0.20 [−0.27 to −0.13]; <i>P</i> &lt; 0.00001). <i>Conclusions</i>. In treatment of patients with AMI, DCB might be a feasible interventional strategy versus control as it associated with comparable clinical outcomes. Future large-volume, well-designed randomized controlled trials to evaluating the role of the DCB in this setting are warranted.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10532429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients","authors":"Yongjun Li,&nbsp;Mingming Yang,&nbsp;Xi Chen,&nbsp;Rui Zhang,&nbsp;Jing Li,&nbsp;Xiaoguo Zhang,&nbsp;Pengfei Zuo,&nbsp;Genshan Ma","doi":"10.1155/2022/4797529","DOIUrl":"10.1155/2022/4797529","url":null,"abstract":"<div>\u0000 <p><i>Aims</i>. To evaluate the regression of coronary atherosclerosis with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in acute coronary syndrome (ACS) patients following primary percutaneous coronary intervention (PPCI). <i>Methods and Result</i>. We examined 40 nontarget lesions in 17 ACS patients who underwent PPCI and were treated with PCSK9 inhibitors. At 1 year, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and atherogenic index (AI) decreased significantly by 2.5 mmol/L, 2.01 mmol/L, and 1.86, respectively. On quantitative coronary angiography, treatment with PCSK9 inhibitors reduced significantly the atherosclerotic area stenosis in nontarget lesions (61.18 ± 14.55 at baseline vs. 52.85 ± 15.51 at 1 year, <i>P</i> &lt; 0.001). <i>Conclusions</i>. After 1 year of PCSK9 inhibition treatment for ACS patients, the area stenosis of non-TLR was considerably reduced.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10786777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome","authors":"Piotr Rola,&nbsp;Adrian Włodarczak,&nbsp;Szymon Włodarczak,&nbsp;Mateusz Barycki,&nbsp;Marek Szudrowicz,&nbsp;Magdalena Łanocha,&nbsp;Łukasz Furtan,&nbsp;Katarzyna Woźnica,&nbsp;Jan Jakub Kulczycki,&nbsp;Joanna Jaroszewska-Pozorska,&nbsp;Michalina Kędzierska,&nbsp;Adrian Doroszko,&nbsp;Maciej Lesiak","doi":"10.1155/2022/5223317","DOIUrl":"10.1155/2022/5223317","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus-eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting. <i>Methods</i>. The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up. <i>Results</i>. There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups. <i>Conclusion</i>. At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10501204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease","authors":"Daisuke Fukamachi,&nbsp;Yasuo Okumura,&nbsp;Naoya Matsumoto,&nbsp;Eizo Tachibana,&nbsp;Koji Oiwa,&nbsp;Makoto Ichikawa,&nbsp;Hironori Haruta,&nbsp;Kazumiki Nomoto,&nbsp;Ken Arima,&nbsp;Atsushi Hirayama","doi":"10.1155/2022/5905022","DOIUrl":"10.1155/2022/5905022","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Current guidelines recommend an oral anticoagulant (OAC) monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and stable coronary artery disease (CAD) 1 year postpercutaneous coronary intervention (PCI). It might be possible to shorten the time for de-escalation from a dual therapy to monotherapy, but data regarding de-escalation to an edoxaban monotherapy are lacking. This study aimed to assess the clinical safety of an edoxaban monotherapy in patients with NVAF and stable CAD. <i>Methods</i>. A multicenter, prospective, randomized, open-label, and parallel group study was established to investigate the safety of an edoxaban monotherapy in patients with NVAF and stable CAD including over 6 months postimplantation of a third-generation DES and 1 year postimplantation of other stents (PRAEDO AF study). Between March 2018 and June 2020, 147 patients from 8 institutions in Japan were randomized to receive either an edoxaban monotherapy (<i>n</i> = 74) or combination therapy (edoxaban plus clopidogrel, <i>n</i> = 73). The primary study endpoint was the composite incidence of major bleeding and clinically significant bleeding, defined according to the ISTH criteria. <i>Results</i>. Major or clinically significant bleeding occurred in 2 patients in the monotherapy group (1.67% per patient-year) and in 5 patients in the combination therapy group (4.28% per patient-year) (hazard ratio, 0.39; 95% confidence interval, 0.08–2.02). There was no incidence of a myocardial infarction, stent thrombosis, unstable angina requiring revascularization, ischemic stroke, systemic stroke, or hemorrhagic stroke in either of the groups. <i>Conclusions</i>. The edoxaban monotherapy was shown to have acceptable clinical safety in patients with NVAF and stable CAD. The study was registered with the Japan Registry of Clinical Trials (jRCTs031180119).</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10508679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between Body Mass Index and Cognitive Function in Patients with Atrial Fibrillation","authors":"Li Guo,&nbsp;Ping Yin,&nbsp;Xiangting Li,&nbsp;Xin Wang,&nbsp;Jing Xue,&nbsp;Wenqing Wang,&nbsp;Dongmei Song,&nbsp;Guomei Xu,&nbsp;Miaomiao Shang,&nbsp;Shuai Liu,&nbsp;Yuanyuan Chen,&nbsp;Qingyun Zhang,&nbsp;Dandan Sun","doi":"10.1155/2022/6025732","DOIUrl":"10.1155/2022/6025732","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Evidence regarding the relationship between body mass index (BMI) and cognitive function was limited. Therefore, the objective of this research is to investigate whether BMI is independently related to cognitive function in Chinese patients with atrial fibrillation after adjusting for other covariates. <i>Methods</i>. The present study is a cross-sectional study. A total of 281 patients with atrial fibrillation who were hospitalized at the Affiliated Hospital of Jining Medical University in Shandong Province from January 2021 to November 2021 were included in the study. The target independent variable and the dependent variable were BMI and cognitive function in patients with atrial fibrillation, respectively. The patients’ general information, BMI, past history, medication history, and other disease-related data were collected. The Montreal cognitive assessment scale (MoCA) was used to evaluate cognitive function. <i>Results</i>. A total of 244 patients with atrial fibrillation were collected in this study, with an average age of (67.28 ± 10.33) years, of whom 55.3% were male. The average BMI was (25.33 ± 4.27) kg/m², and the average cognitive function score was (19.25 ± 6.88) points. The results of the smooth curve fitting and threshold effect tests showed that there was a curve correlation between BMI and cognitive function score, and its inflection point was 24.56 kg/m². To the left of the inflection point, the relationship was significant; the effect size and the confidence interval were 0.43 and 0.01–0.85, respectively. To the right of the inflection point, there was no significant correlation between BMI and cognitive function (<i>P</i> = 0.152). <i>Conclusion</i>. When BMI is lower than 24.56 kg/m², the cognitive function score increases by 0.43 points for each unit increase in BMI in patients with atrial fibrillation. An increase in BMI at this time is a protective factor for cognitive function. Within the normal range of BMI, the higher the BMI in atrial fibrillation patients, the higher the cognitive function score. We encourage atrial fibrillation patients with normal BMI to maintain their current weight.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10564902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis","authors":"Lidija Savic,&nbsp;Igor Mrdovic,&nbsp;Milika Asanin,&nbsp;Sanja Stankovic,&nbsp;Ratko Lasica,&nbsp;Gordana Krljanac,&nbsp;Dubravka Rajic,&nbsp;Damjan Simic","doi":"10.1155/2022/5815274","DOIUrl":"10.1155/2022/5815274","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. The objective of this study is to analyze the impact of declining kidney function on the occurrence of the slow-flow/no-reflow phenomenon in patients with ST-elevation myocardial infarction (STEMI) treated with primary PCI (pPCI), as well as the analysis of the prognostic impact of the slow-flow/no-reflow phenomenon on short- and long-term mortality in these patients. <i>Methods</i>. We analyzed 3,115 consecutive patients. A value of the glomerular filtration rate (eGFR) at the time of admission of eGFR &lt;90 ml/min/m² was considered a low baseline eGFR. The follow-up period was 8 years. <i>Results</i>. The slow-flow/no-reflow phenomenon through the IRA was registered in 146 (4.7%) patients. Estimated GFR of &lt;90 ml/min/m² was an independent predictor for the occurrence of the slow-flow/no-reflow phenomenon (OR 2.91, 95% CI 1.25–3.95, <i>p</i> &lt; 0.001), and the risk for the occurrence of the slow-flow/no-reflow phenomenon increased with the decline of the kidney function: eGFR 60–89 ml/min/m²: OR 1.94 (95% CI 1.22–3.07, <i>p</i> = 0.005), eGFR 45–59 ml/min/m²: OR 2.55 (95% CI 1.55–4.94, <i>p</i> &lt; 0.001), eGFR 30–44 ml/min/m²: OR 2.77 (95% CI 1.43–5.25, <i>p</i> &lt; 0.001), eGFR 15–29 ml/min/m²: OR 5.84 (95% CI 2.84–8.01, <i>p</i> &lt; 0.001). The slow-flow/no-reflow phenomenon was a strong independent predictor of short- and long-term all-cause mortality: 30-day mortality (HR 2.62, 95% CI 1.78–3.57, <i>p</i> &lt; 0.001) and 8-year mortality (HR 2.09, 95% CI 1.49–2.09, <i>p</i> &lt; 0.001). <i>Conclusion</i>. Reduced baseline kidney function was an independent predictor for the occurrence of the slow-flow/no-reflow phenomenon, and its prognostic impact started with the mildest decrease in eGFR (below 90 ml/min/m²) and increased with its further decline. The slow-flow/no-reflow phenomenon was a strong independent predictor of mortality in the short- and long-term follow-up of the analyzed patients.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10399004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the Angle of the Left Subclavian Artery and Procedural Time for Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome","authors":"Masatsugu Miyagawa,&nbsp;Daisuke Fukamachi,&nbsp;Katsunori Fukumoto,&nbsp;Masaki Monden,&nbsp;Kurara Takahashi,&nbsp;Shohei Migita,&nbsp;Saki Mizobuchi,&nbsp;Yudai Tanaka,&nbsp;Akihito Ogaku,&nbsp;Yutaka Koyama,&nbsp;Hidesato Fujito,&nbsp;Riku Arai,&nbsp;Norio Takei,&nbsp;Keisuke Kojima,&nbsp;Korehito Iida,&nbsp;Nobuhiro Murata,&nbsp;Yasuo Okumura","doi":"10.1155/2022/3249745","DOIUrl":"10.1155/2022/3249745","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. The effect of left subclavian artery tortuosity during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) remains unclear. <i>Methods</i>. Of 245 ACS patients (from November 2019 and May 2021), 79 who underwent PCI via a left radial approach (LRA) were included. We measured the angle of the left subclavian artery in the coronal view on CT imaging as an indicator of the tortuosity and investigated the association between that angle and the clinical variables and procedural time. <i>Results</i>. Patients with a left subclavian artery angle of a median of &lt;70 degrees (severe tortuosity) were older (75.4 ± 11.7 vs. 62.9 ± 12.3 years, <i>P</i> &lt; 0.001) and had a higher prevalence of female sex (42.1% vs. 14.6%, <i>P</i> = 0.007), hypertension (94.7% vs. 75.6%, <i>P</i> = 0.02), and subclavian artery calcification (73.7% vs. 34.2%, <i>P</i> &lt; 0.001) than those with that ≥70 degrees. The left subclavian artery angle correlated negatively with the sheath cannulation to the first balloon time (<i>ρ</i> = −0.51, <i>P</i> &lt; 0.001) and total procedural time (<i>ρ</i> = −0.32, <i>P</i> = 0.004). A multiple linear regression analysis revealed that the natural log transformation of the sheath insertion to first balloon time was associated with a subclavian artery angle of &lt;70 degrees (<i>β</i> = 0.45, <i>P</i> &lt; 0.001). <i>Conclusion</i>. Our study showed that lower left subclavian artery angles as a marker of the tortuosity via the LRA were strongly associated with a longer sheath insertion to balloon time and subsequent entire procedure time during the PCI.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10349157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective Use of Pulmonary Vasodilators in Patients with Fontan Physiology","authors":"Thomas Glenn,&nbsp;Nicole Duster,&nbsp;Jerry Dwek,&nbsp;Jose Silva-Sepulveda,&nbsp;Howaida G. El-Said","doi":"10.1155/2022/7602793","DOIUrl":"10.1155/2022/7602793","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Fontan-associated liver disease is a well-known sequela following the Fontan procedure for patients living with single-ventricle heart disease. Pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors, have emerged as a potential therapeutic option for lowering central venous pressures by reducing pulmonary vascular resistance. <i>Method</i>. We performed a single-center retrospective review of Fontan patients who were placed on pulmonary vasodilator therapy with prehemodynamic and posthemodynamic, MR elastography, and histologic assessments. <i>Results</i>. A total of 125 patients with Fontan circulation underwent surveillance with cardiac catheterization during the review period. Fifty-three (42%) patients who did not have increased end-diastolic pressures at the time of cardiac catheterization were started on phosphodiesterase type 5 inhibitor therapy. Nine patients (17%) underwent posttherapy follow-up catheterization. The mean Fontan pressure decreased from 15.4 ± 3.3 mmHg to 13.3 ± 2.5 mmHg (<i>p</i> = 0.026), after initiation of pulmonary vasodilatory therapy. There was no change in end-diastolic pressure, transpulmonary gradient, wedge pressure, pulmonary vascular resistance, cardiac index, or saturation. Eleven patients (21%) underwent pretherapy MR elastography testing with posttherapy follow-up MR elastography. We found no improvement in liver stiffness score following the application of pulmonary vasodilators. Three patients underwent pretherapy and posttherapy liver biopsies, with variable histological changes observed within the hepatic parenchyma. <i>Conclusions</i>. These data demonstrate indeterminate results for the selective use of pulmonary vasodilators but highlight the need for large prospective randomized control trials of pulmonary vasodilator therapies to fully assess the benefit of such therapies in Fontan-associated liver disease.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40723076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Impella CP versus VA-ECMO in Patients Undergoing Complex High-Risk Indicated PCI","authors":"Deborah M.F. van den Buijs,&nbsp;Adriaan Wilgenhof,&nbsp;Paul Knaapen,&nbsp;Carlo Zivelonghi,&nbsp;Tom Meijers,&nbsp;Paul Vermeersch,&nbsp;Fatih Arslan,&nbsp;Niels Verouden,&nbsp;Alex Nap,&nbsp;Krischan Sjauw,&nbsp;Floris S. van den Brink","doi":"10.1155/2022/8167011","DOIUrl":"10.1155/2022/8167011","url":null,"abstract":"<div>\u0000 <p><i>Objectives</i>. To compare two different forms of mechanical circulatory support (MCS) in patients with complex high-risk indicated PCI (CHIP): the Impella CP system and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). <i>Background</i>. To prevent hemodynamic instability in CHIP, various MCS systems are available. However, comparable data on different forms of MCS are not at hand. <i>Methods</i>. In this multicenter observational study, we retrospectively evaluated all CHIP procedures with the support of an Impella CP or VA-ECMO, who were declined surgery by the heart team. Major adverse cardiac events (MACE), mortality at discharge, and 30-day mortality were evaluated. <i>Results</i>. A total of 41 patients were included, of which 27 patients were supported with Impella CP and 14 patients with VA-ECMO. Baseline characteristics were well-balanced in both groups. No significant difference in periprocedural hemodynamic instability was observed between both groups (3.7% vs. 14.3%; <i>p</i> = 0.22). The composite outcome of MACE showed no significant difference (30.7% vs. 21.4%; <i>p</i> = 0.59). Bleeding complications were higher in the Impella CP group, but showed no significant difference (22.2% vs. 7.1%; <i>p</i> = 0.22) and occurred more at the non-Impella access site. In-hospital mortality was 7.4% in the Impella CP group versus 14.3% in the VA-ECMO group and showed no significant difference (<i>p</i> = 0.48). 30-Day mortality showed no significant difference (7.4% vs. 21.4%; <i>p</i> = 0.09). <i>Conclusions</i>. In patients with CHIP, there were no significant differences in hemodynamic instability and overall MACE between VA-ECMO or Impella CP device as mechanical circulatory support. Based on this study, the choice of either VA-ECMO or Impella CP does not alter the outcome.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40723077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles Therapy for Pulmonary Hypertension: A Comprehensive Review of Preclinical Studies","authors":"Ji-Hong Xu,&nbsp;Jia-Ping Liang,&nbsp;Chu-Jun Zhu,&nbsp;Yu-Jun Lian","doi":"10.1155/2022/5451947","DOIUrl":"10.1155/2022/5451947","url":null,"abstract":"<div>\u0000 <p>Pulmonary hypertension (PH) is a type of clinical pathophysiological syndrome characterized by a progressive increase in pulmonary vascular resistance and subsequent progressive failure of the right heart function, and is a common complication of many diseases. Mesenchymal stem cells (MSCs) autonomously home to sites damaged by disease, repair damaged tissues, and participate in the regulation of systemic inflammation and immune responses, which have good clinical application prospects. Extracellular vesicles (EVs), such as exosomes and microvesicles, participate in various biological activities by regulating intercellular communication. Exosomes secreted into the extracellular environment also affect the host immune system. MSC-derived extracellular vesicles (MSC-EVs), as a mediator in the paracrine processes of MSCs, carry biologically active substances such as proteins, lipids, mRNA, and micro-RNA. MSC-EVs therapies, safer than cell-based treatments, have been shown to be effective in modulating macrophages to support anti-inflammatory phenotypes, which are strongly related to histological and functional benefits in preclinical models of pulmonary hypertension. The main effects of active substances and their potential medical value have attracted wide attention from researchers. This article reviews the role and relevant mechanisms of MSC-EVs in the treatment of pulmonary hypertension in recent studies and provides a basis for their future clinical applications.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2022 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40703303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}